Targeted Strategies for Today's Evolving Markets

MissionIR Blog

NeoGenomics, Inc. (NEO) Launches Tests for Profiling of Myelodysplastic Syndrome

NeoGenomics is a leading clinical laboratory that specializes in cancer genetics testing, the fastest growing segment of the laboratory industry. The company’s testing services include: cytogenetics, morphology studies, anatomic pathology, flow cytometry, immunohistochemistry, fluorescence in-situ hybridization, and molecular genetic testing.

The company announced today it had validated and introduced a number of clinical molecular tests for the comprehensive profiling of myelodysplastic syndrome (MDS). MDS is a complex and hard-to-diagnose disease because of its wide range of clinical behaviors. It is myeloid malignancy characterized by peripheral blood cytopenias. The disease can arise de novo or after therapies for other cancers such as chemo or radiation therapies. It is diagnosed in more than 10,000 people annually in the U.S.

NeoGenomics’ comprehensive MDS testing covers all of the known relevant molecular mutations associated with the disease. The company now provides mutation analysis of the following genes: SF3B1, U2AF1, SRSF2, ZRSR2, RUNX1, EZH2, ASXL1, TET2, TP53, NRAS, CBL, PTPN11, IDH1/2, and ETV6. The genes can be analyzed individually or as a group. NeoGenomics’ tests can provide profound insights into the disease and guide physicians in designing the proper personalized therapeutic strategies for each individual patient.

The new MDS tests mean the company now offers the most extensive menu of molecular testing services focused on cancer in the U.S. The tests are part of NeoGenomics’ strategy to become the leading laboratory in the quickly evolving field of molecular pathology. For additional information about NeoGenomics, its new MDS tests, and its entire range of testing services, please visit

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Comments are closed.